Patent intelligence · US
US 9539228
Composition containing lysine as a nutritional supplement or treatment in the case of herpes
Composition containing lysine as a nutritional supplement or treatment in the case of herpes
Patent details — US 9539228
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 10, 2017
- Expiration
- Jan 5, 2037
- Applicant
- Reiner Rittinghausen
- Claims
- 19
- CPC classes
- A61K, A61K31/198, A61K31/375, A61K31/4415
Quick answer
US 9539228 (Composition containing lysine as a nutritional supplement or treatment in the case of herpes) is held by Reiner Rittinghausen. Status: granted. Granted Jan 10, 2017. Expires Jan 5, 2037 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Reiner Rittinghausen
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/198, A61K31/375, A61K31/4415, A61K31/519, A61K31/525
More from Reiner Rittinghausen
Related pharmaceutical patents in our USPTO index.
-
US 12390512
Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae
granted -
US 11033623
Magnetic stem cell therapy for lesions
granted -
US 10472381
Sialic acid derivatives
granted -
US 10265396
Magnetic extracellular matrix
granted -
US 8309071
Foamy viral envelope genes
granted -
US 8293803
Retinoid compounds and their use
granted -
US 8268792
Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases
granted
Frequently asked questions
What is US patent 9539228?
US 9539228 (Composition containing lysine as a nutritional supplement or treatment in the case of herpes) is held by Reiner Rittinghausen. Status: granted. Granted Jan 10, 2017. Expires Jan 5, 2037 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9539228?
Reiner Rittinghausen is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 9539228 expire?
Our index shows an expiration date of Jan 5, 2037 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.